Cargando…
Mesalazine treatment causing resolution of intracranial hypertension secondary to ulcerative colitis: A case report
RATIONALE: The association between intracranial hypertension (ICH) and ulcerative colitis (UC) is rare. We report the unusual case of a male patient with UC and ICH in whom both conditions resolved with mesalazine therapy. PATIENT CONCERNS: A 48-year-old Caucasian man presented to our department in...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310519/ https://www.ncbi.nlm.nih.gov/pubmed/30544405 http://dx.doi.org/10.1097/MD.0000000000013365 |
_version_ | 1783383451276148736 |
---|---|
author | Khanna, Raoul Kanav Hage, Rabih Hage, Alexandre Polin, Vanessa Sené, Thomas Vignal-Clermont, Catherine |
author_facet | Khanna, Raoul Kanav Hage, Rabih Hage, Alexandre Polin, Vanessa Sené, Thomas Vignal-Clermont, Catherine |
author_sort | Khanna, Raoul Kanav |
collection | PubMed |
description | RATIONALE: The association between intracranial hypertension (ICH) and ulcerative colitis (UC) is rare. We report the unusual case of a male patient with UC and ICH in whom both conditions resolved with mesalazine therapy. PATIENT CONCERNS: A 48-year-old Caucasian man presented to our department in June 2016 for decreased vision, transient visual obscuration, pulsatile tinnitus and headaches of 7 months duration. Bilateral optic disc swelling was found at fundus examination. Brain MRI excluded any brain tumor and lumbar puncture showed cerebrospinal fluid (CSF) opening pressure of 26 cm of water with normal CSF contents. DIAGNOSES: Idiopathic ICH was suspected. INTERVENTIONS: The patient was managed with oral acetazolamide. Headaches initially improved but the dosage could not be decreased under 750 mg a day without recurrence of the symptoms. Extensive review of systems showed that the patient had active UC. He was given oral mesalazine, 2000 mg a day. OUTCOMES: The symptoms of UC and ICH quickly resolved. Acetazolamide was progressively tapered over the course of the 9 subsequent months and the patient did not show any worsening of his symptoms or papilledema. LESSONS: UC should be added to the list of disorders associated with ICH. In case of atypical ICH with drug dependency, investigations should seek for UC. Treating efficiently UC with mesalazine may improve ICH, suggesting an underlying inflammatory process. |
format | Online Article Text |
id | pubmed-6310519 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-63105192019-01-14 Mesalazine treatment causing resolution of intracranial hypertension secondary to ulcerative colitis: A case report Khanna, Raoul Kanav Hage, Rabih Hage, Alexandre Polin, Vanessa Sené, Thomas Vignal-Clermont, Catherine Medicine (Baltimore) Research Article RATIONALE: The association between intracranial hypertension (ICH) and ulcerative colitis (UC) is rare. We report the unusual case of a male patient with UC and ICH in whom both conditions resolved with mesalazine therapy. PATIENT CONCERNS: A 48-year-old Caucasian man presented to our department in June 2016 for decreased vision, transient visual obscuration, pulsatile tinnitus and headaches of 7 months duration. Bilateral optic disc swelling was found at fundus examination. Brain MRI excluded any brain tumor and lumbar puncture showed cerebrospinal fluid (CSF) opening pressure of 26 cm of water with normal CSF contents. DIAGNOSES: Idiopathic ICH was suspected. INTERVENTIONS: The patient was managed with oral acetazolamide. Headaches initially improved but the dosage could not be decreased under 750 mg a day without recurrence of the symptoms. Extensive review of systems showed that the patient had active UC. He was given oral mesalazine, 2000 mg a day. OUTCOMES: The symptoms of UC and ICH quickly resolved. Acetazolamide was progressively tapered over the course of the 9 subsequent months and the patient did not show any worsening of his symptoms or papilledema. LESSONS: UC should be added to the list of disorders associated with ICH. In case of atypical ICH with drug dependency, investigations should seek for UC. Treating efficiently UC with mesalazine may improve ICH, suggesting an underlying inflammatory process. Wolters Kluwer Health 2018-12-10 /pmc/articles/PMC6310519/ /pubmed/30544405 http://dx.doi.org/10.1097/MD.0000000000013365 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | Research Article Khanna, Raoul Kanav Hage, Rabih Hage, Alexandre Polin, Vanessa Sené, Thomas Vignal-Clermont, Catherine Mesalazine treatment causing resolution of intracranial hypertension secondary to ulcerative colitis: A case report |
title | Mesalazine treatment causing resolution of intracranial hypertension secondary to ulcerative colitis: A case report |
title_full | Mesalazine treatment causing resolution of intracranial hypertension secondary to ulcerative colitis: A case report |
title_fullStr | Mesalazine treatment causing resolution of intracranial hypertension secondary to ulcerative colitis: A case report |
title_full_unstemmed | Mesalazine treatment causing resolution of intracranial hypertension secondary to ulcerative colitis: A case report |
title_short | Mesalazine treatment causing resolution of intracranial hypertension secondary to ulcerative colitis: A case report |
title_sort | mesalazine treatment causing resolution of intracranial hypertension secondary to ulcerative colitis: a case report |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310519/ https://www.ncbi.nlm.nih.gov/pubmed/30544405 http://dx.doi.org/10.1097/MD.0000000000013365 |
work_keys_str_mv | AT khannaraoulkanav mesalazinetreatmentcausingresolutionofintracranialhypertensionsecondarytoulcerativecolitisacasereport AT hagerabih mesalazinetreatmentcausingresolutionofintracranialhypertensionsecondarytoulcerativecolitisacasereport AT hagealexandre mesalazinetreatmentcausingresolutionofintracranialhypertensionsecondarytoulcerativecolitisacasereport AT polinvanessa mesalazinetreatmentcausingresolutionofintracranialhypertensionsecondarytoulcerativecolitisacasereport AT senethomas mesalazinetreatmentcausingresolutionofintracranialhypertensionsecondarytoulcerativecolitisacasereport AT vignalclermontcatherine mesalazinetreatmentcausingresolutionofintracranialhypertensionsecondarytoulcerativecolitisacasereport |